Company: PSTV
Filing Date: 2025-06-09
Form Type: DRS
Source: 0000950123-25-005986
Chunk: 3

Company: PLUS THERAPEUTICS, INC.
Filing Date: 2025-06-09
Form: DRS
Chunk 3
---
 described in the “ Risk Factors” section on page 3 of this prospectus. You should also consider the risk factors described or referred to in any documents incorporated by reference in this prospectus, and in any applicable prospectus supplement, before investing in these securities.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.

The date of this prospectus is , 2025

Confidential Treatment Requested by Plus Therapeutics, Inc. Pursuant to 17 C.F.R. Section 200.83 TABLE OF CONTENTS

| ABOUT THIS PROSPECTUS                                                               |     | ii |
| PROSPECTUS SUMMARY                                                                  |     |  1 |
| THE OFFERING                                                                        |     |  2 |
| FORWARD-LOOKING STATEMENTS                                                          |     |  6 |
| THE LINCOLN PARK TRANSACTION                                                        |     |  7 |
| USE OF PROCEEDS                                                                     |     | 13 |
| DILUTION                                                                            |     | 14 |
| THE SELLING STOCKHOLDER                                                             |     | 15 |
| MARKET PRICE OF OUR COMMON STOCK AND RELATED STOCKHOLDER                            
 MATTERS                                                                             |     | 17 |
| DESCRIPTION OF CAPITAL STOCK                                                        |     | 18 |
| PLAN OF DISTRIBUTION                                                                |     | 23 |
| LEGAL MATTERS                                                                       |     | 25 |
| EXPERTS                                                                             |     | 25 |
| WHERE YOU CAN FIND MORE INFORMATION                                                 |     | 25 |
| INCORPORATION BY REFERENCE                                                          |     | 26 |
| DISCLOSURE OF COMMISSION POSITION ON INDEMNIFICATION FOR SECURITIES ACT LIABILITIES |     | 27 |

i

Confidential Treatment Requested by Plus Therapeutics, Inc.

Pursuant to 17 C.F.R. Section 200.83

ABOUT THIS PROSPECTUS

This prospectus forms part of a registration statement that we filed with the Securities and Exchange Commission (the “SEC”), and
that includes exhibits that provide more detail of the matters discussed in this prospectus. You should read this prospectus and the related exhibits filed with the SEC, together with the additional information described under the headings
“Where You Can Find More Information” and “Incorporation by Reference” before making your investment decision.

You
should rely only on the information provided in this prospectus or in a prospect